A retrospective study evaluating the impact of infectious complications during azacitidine treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-05-04

AUTHORS

Anna Schuck, Marie-Christine Goette, Judith Neukirchen, Andrea Kuendgen, Norbert Gattermann, Thomas Schroeder, Guido Kobbe, Ulrich Germing, Rainer Haas

ABSTRACT

Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69 years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81 cycles with at least one IC. The median number of administered cycles was 6 (range 1–43). Median OS after the start of azacitidine was 17 months (range 1–103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients’ hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4–6 cycles. More... »

PAGES

1097-1104

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2

DOI

http://dx.doi.org/10.1007/s00277-017-3001-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085177784

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28474144


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Infective Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Length of Stay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment, Health Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schuck", 
        "givenName": "Anna", 
        "id": "sg:person.07532014665.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07532014665.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goette", 
        "givenName": "Marie-Christine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neukirchen", 
        "givenName": "Judith", 
        "id": "sg:person.0643404664.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuendgen", 
        "givenName": "Andrea", 
        "id": "sg:person.01022105364.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "Norbert", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schroeder", 
        "givenName": "Thomas", 
        "id": "sg:person.01271136615.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271136615.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobbe", 
        "givenName": "Guido", 
        "id": "sg:person.01164073234.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164073234.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "Rainer", 
        "id": "sg:person.01127414674.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00277-016-2649-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038586565", 
          "https://doi.org/10.1007/s00277-016-2649-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01703109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036298304", 
          "https://doi.org/10.1007/bf01703109"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-05-04", 
    "datePublishedReg": "2017-05-04", 
    "description": "Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69\u00a0years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81\u00a0cycles with at least one IC. The median number of administered cycles was 6 (range 1\u201343). Median OS after the start of azacitidine was 17\u00a0months (range 1\u2013103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients\u2019 hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4\u20136\u00a0cycles.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-017-3001-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "96"
      }
    ], 
    "keywords": [
      "incidence of IC", 
      "infectious complications", 
      "overall survival", 
      "hematological response", 
      "stable disease", 
      "high-risk myelodysplastic syndrome", 
      "more infectious complications", 
      "median overall survival", 
      "longer overall survival", 
      "success of therapy", 
      "azacitidine cycles", 
      "microbiological documentation", 
      "most patients", 
      "clinical course", 
      "azacitidine treatment", 
      "myelodysplastic syndrome", 
      "clinical workup", 
      "retrospective study", 
      "available therapies", 
      "outpatient setting", 
      "antimicrobial therapy", 
      "median number", 
      "azacitidine", 
      "infection rate", 
      "antimicrobial treatment", 
      "bacterial infections", 
      "older age", 
      "hospital", 
      "disease", 
      "response evaluation", 
      "therapy", 
      "complications", 
      "IC rates", 
      "patients", 
      "incidence", 
      "survival", 
      "age", 
      "days", 
      "treatment", 
      "significant improvement", 
      "low levels", 
      "comorbidities", 
      "response", 
      "IPSS", 
      "syndrome", 
      "workup", 
      "infection", 
      "considerable number", 
      "severity", 
      "months", 
      "rate", 
      "MDS", 
      "setting", 
      "course", 
      "levels", 
      "long time", 
      "evaluation", 
      "start", 
      "study", 
      "number", 
      "occurrence", 
      "impact", 
      "cycle", 
      "improvement", 
      "documentation", 
      "types", 
      "success", 
      "time", 
      "influence"
    ], 
    "name": "A retrospective study evaluating the impact of infectious complications during azacitidine treatment", 
    "pagination": "1097-1104", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085177784"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-017-3001-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28474144"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-017-3001-2", 
      "https://app.dimensions.ai/details/publication/pub.1085177784"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_757.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-017-3001-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      113 URIs      103 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-017-3001-2 schema:about N06f08fabbed44d1f818cb930fa1addf8
2 N214144bd7e3d45c2ae1c992d2dafd275
3 N393b3b3d769a4e77b7e9a0194cfc288c
4 N396834f4a09d4b4b9b0574eb8b80806f
5 N3b9c3c626579487fa9a5f6ff1bc9c86d
6 N3f6bac5fe62b46168b2664e8dbcc8625
7 N6a9a7fe04de04bbd903cc1709542f426
8 N6cc494fc3d244ffca0a3053fe5dd8035
9 N6dbb8ec3714f46878bd1da4eb47e3f73
10 N7bf59ec461b643c983a95a9f10d07b33
11 N7fcb8157328047018149eb644bced59d
12 N8b7faca7886d464b89c78a6b2b40c85b
13 N8fd61f42015f42c3aa3a7a3ce2f3218e
14 N97a5703e091b4815973bc842884ae11f
15 Nd70f793cdfe1497f82f98209266398e3
16 Ne9c806d6fe234c5dbda382d9139480ff
17 Nf759732e2c094e918aa7c4414a13d42d
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Nc98ff12729224790aaf864547e7cea91
21 schema:citation sg:pub.10.1007/bf01703109
22 sg:pub.10.1007/s00277-016-2649-3
23 schema:datePublished 2017-05-04
24 schema:datePublishedReg 2017-05-04
25 schema:description Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69 years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81 cycles with at least one IC. The median number of administered cycles was 6 (range 1–43). Median OS after the start of azacitidine was 17 months (range 1–103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients’ hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4–6 cycles.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N217e5298ebd94ecd8fc326a35f81f646
29 N399a2849ef9d4829b2cfeb1cda0196e5
30 sg:journal.1358129
31 schema:keywords IC rates
32 IPSS
33 MDS
34 age
35 antimicrobial therapy
36 antimicrobial treatment
37 available therapies
38 azacitidine
39 azacitidine cycles
40 azacitidine treatment
41 bacterial infections
42 clinical course
43 clinical workup
44 comorbidities
45 complications
46 considerable number
47 course
48 cycle
49 days
50 disease
51 documentation
52 evaluation
53 hematological response
54 high-risk myelodysplastic syndrome
55 hospital
56 impact
57 improvement
58 incidence
59 incidence of IC
60 infection
61 infection rate
62 infectious complications
63 influence
64 levels
65 long time
66 longer overall survival
67 low levels
68 median number
69 median overall survival
70 microbiological documentation
71 months
72 more infectious complications
73 most patients
74 myelodysplastic syndrome
75 number
76 occurrence
77 older age
78 outpatient setting
79 overall survival
80 patients
81 rate
82 response
83 response evaluation
84 retrospective study
85 setting
86 severity
87 significant improvement
88 stable disease
89 start
90 study
91 success
92 success of therapy
93 survival
94 syndrome
95 therapy
96 time
97 treatment
98 types
99 workup
100 schema:name A retrospective study evaluating the impact of infectious complications during azacitidine treatment
101 schema:pagination 1097-1104
102 schema:productId N2de75bb170264c009f1492d4109806ff
103 N572ac4f2cf4f4940b6bec2f328f3850a
104 Nbfb61040f0c84b2bbdef1e3c1efaee4e
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085177784
106 https://doi.org/10.1007/s00277-017-3001-2
107 schema:sdDatePublished 2022-10-01T06:43
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher N1db2e5a77f354697bf8bbaa7368ab7be
110 schema:url https://doi.org/10.1007/s00277-017-3001-2
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N06f08fabbed44d1f818cb930fa1addf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Male
116 rdf:type schema:DefinedTerm
117 N19e8aca0fda944d6b1386ec1fef88e6f rdf:first sg:person.01362464041.20
118 rdf:rest N80cc2e995d29422fa91c8e3d77d202ba
119 N1db2e5a77f354697bf8bbaa7368ab7be schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N214144bd7e3d45c2ae1c992d2dafd275 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Female
123 rdf:type schema:DefinedTerm
124 N217e5298ebd94ecd8fc326a35f81f646 schema:issueNumber 7
125 rdf:type schema:PublicationIssue
126 N24abc08d37c04e3f884ae06a7b5a5c3d rdf:first sg:person.01271136615.68
127 rdf:rest Nbb9f51409e324373b3d7f8f092127825
128 N2de75bb170264c009f1492d4109806ff schema:name dimensions_id
129 schema:value pub.1085177784
130 rdf:type schema:PropertyValue
131 N393b3b3d769a4e77b7e9a0194cfc288c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Kaplan-Meier Estimate
133 rdf:type schema:DefinedTerm
134 N396834f4a09d4b4b9b0574eb8b80806f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Middle Aged
136 rdf:type schema:DefinedTerm
137 N399a2849ef9d4829b2cfeb1cda0196e5 schema:volumeNumber 96
138 rdf:type schema:PublicationVolume
139 N3b9c3c626579487fa9a5f6ff1bc9c86d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Bacterial Infections
141 rdf:type schema:DefinedTerm
142 N3f6bac5fe62b46168b2664e8dbcc8625 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Aged
144 rdf:type schema:DefinedTerm
145 N572ac4f2cf4f4940b6bec2f328f3850a schema:name doi
146 schema:value 10.1007/s00277-017-3001-2
147 rdf:type schema:PropertyValue
148 N6a9a7fe04de04bbd903cc1709542f426 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Retrospective Studies
150 rdf:type schema:DefinedTerm
151 N6cc494fc3d244ffca0a3053fe5dd8035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Antimetabolites, Antineoplastic
153 rdf:type schema:DefinedTerm
154 N6d6f44c5cdb34965874d3e3074a3369c rdf:first sg:person.01273447501.34
155 rdf:rest N24abc08d37c04e3f884ae06a7b5a5c3d
156 N6dbb8ec3714f46878bd1da4eb47e3f73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Outcome Assessment, Health Care
158 rdf:type schema:DefinedTerm
159 N7b6037fcccd643159bc4899318bfa52d rdf:first N9def27a05531457dbde4661299a5ff61
160 rdf:rest Ne5aded591ed54b45bd84558c64a0b600
161 N7bf59ec461b643c983a95a9f10d07b33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Myelodysplastic Syndromes
163 rdf:type schema:DefinedTerm
164 N7fcb8157328047018149eb644bced59d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Adult
166 rdf:type schema:DefinedTerm
167 N80cc2e995d29422fa91c8e3d77d202ba rdf:first sg:person.01127414674.14
168 rdf:rest rdf:nil
169 N8b7faca7886d464b89c78a6b2b40c85b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Risk Factors
171 rdf:type schema:DefinedTerm
172 N8fd61f42015f42c3aa3a7a3ce2f3218e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Anti-Infective Agents
174 rdf:type schema:DefinedTerm
175 N97a5703e091b4815973bc842884ae11f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Azacitidine
177 rdf:type schema:DefinedTerm
178 N9def27a05531457dbde4661299a5ff61 schema:affiliation grid-institutes:grid.411327.2
179 schema:familyName Goette
180 schema:givenName Marie-Christine
181 rdf:type schema:Person
182 Nbb9f51409e324373b3d7f8f092127825 rdf:first sg:person.01164073234.53
183 rdf:rest N19e8aca0fda944d6b1386ec1fef88e6f
184 Nbfb61040f0c84b2bbdef1e3c1efaee4e schema:name pubmed_id
185 schema:value 28474144
186 rdf:type schema:PropertyValue
187 Nc98ff12729224790aaf864547e7cea91 rdf:first sg:person.07532014665.37
188 rdf:rest N7b6037fcccd643159bc4899318bfa52d
189 Nd70f793cdfe1497f82f98209266398e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Aged, 80 and over
191 rdf:type schema:DefinedTerm
192 Nd7e5ef0bf19f4cc1a7bff18515aac5c5 rdf:first sg:person.01022105364.01
193 rdf:rest N6d6f44c5cdb34965874d3e3074a3369c
194 Ne5aded591ed54b45bd84558c64a0b600 rdf:first sg:person.0643404664.08
195 rdf:rest Nd7e5ef0bf19f4cc1a7bff18515aac5c5
196 Ne9c806d6fe234c5dbda382d9139480ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Humans
198 rdf:type schema:DefinedTerm
199 Nf759732e2c094e918aa7c4414a13d42d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Length of Stay
201 rdf:type schema:DefinedTerm
202 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
203 schema:name Medical and Health Sciences
204 rdf:type schema:DefinedTerm
205 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
206 schema:name Clinical Sciences
207 rdf:type schema:DefinedTerm
208 sg:journal.1358129 schema:issn 0939-5555
209 1432-0584
210 schema:name Annals of Hematology
211 schema:publisher Springer Nature
212 rdf:type schema:Periodical
213 sg:person.01022105364.01 schema:affiliation grid-institutes:grid.411327.2
214 schema:familyName Kuendgen
215 schema:givenName Andrea
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01
217 rdf:type schema:Person
218 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
219 schema:familyName Haas
220 schema:givenName Rainer
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
222 rdf:type schema:Person
223 sg:person.01164073234.53 schema:affiliation grid-institutes:grid.411327.2
224 schema:familyName Kobbe
225 schema:givenName Guido
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164073234.53
227 rdf:type schema:Person
228 sg:person.01271136615.68 schema:affiliation grid-institutes:grid.411327.2
229 schema:familyName Schroeder
230 schema:givenName Thomas
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271136615.68
232 rdf:type schema:Person
233 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
234 schema:familyName Gattermann
235 schema:givenName Norbert
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
237 rdf:type schema:Person
238 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
239 schema:familyName Germing
240 schema:givenName Ulrich
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
242 rdf:type schema:Person
243 sg:person.0643404664.08 schema:affiliation grid-institutes:grid.411327.2
244 schema:familyName Neukirchen
245 schema:givenName Judith
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08
247 rdf:type schema:Person
248 sg:person.07532014665.37 schema:affiliation grid-institutes:grid.411327.2
249 schema:familyName Schuck
250 schema:givenName Anna
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07532014665.37
252 rdf:type schema:Person
253 sg:pub.10.1007/bf01703109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036298304
254 https://doi.org/10.1007/bf01703109
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/s00277-016-2649-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038586565
257 https://doi.org/10.1007/s00277-016-2649-3
258 rdf:type schema:CreativeWork
259 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany
260 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...